What makes a good biomarker?
Journal Title: Advances in Precision Medicine - Year 2016, Vol 1, Issue 1
Abstract
The last decade has seen an extraordinary amount of effort devoted in biomedical research to the field of biomarkers. There have been some notable successes with novel markers being adopted into clinical practice bringing clear clinical benefit to some patients — particularly with the increasing numbers of medicines being approved with companion diagnostics. However, it is fair to say that there has not yet been the numbers of clinically valuable biomarkers brought to medical practice that the research effort would seem to warrant. This paper evaluates examples of successful biomarkers, markers which might be considered partial successes and a few problematic examples and argues that more effort spent in the validation phase of marker development, and less in the discovery phase might be a more efficient way to allocate research resources.
Authors and Affiliations
Robert L Holland
Keywords
Related Articles
- EP ID EP679274
- DOI -
- Views 176
- Downloads 0
Personalized medicine: consequences for drug research and therapy
In drug research, a serious transformation has taken place. With increasing knowledge gained from molecular medicine, it became possible to refine and develop new therapies based on the molecular mechanisms of diseases....
Validation of novel multiplex technologies
Cytokine and chemokine levels in body fluid provide information of altered conditions in patients. The parallel analysis of multiple factors, such as cytokines, from small sample sizes is an interesting approach for the...
Investigating the health-economic profiles of biomarker-driven immunosuppresion (BIO-DrIM) following solid organ transplantation
Immunosuppression (IS) following solid organ transplantation is indicated to avoid rejection but puts a significant burden on patients and healthcare systems due to life-long medication dependency and associated costs. O...
The SMART healthcare solution
Substitutable Medical Apps Reusable Technologies (SMART®) on Fast Healthcare Interoperability Resources (FHIR) is an open, standards platform that allows third parties to build health applications that interact with elec...
What makes a good biomarker?
The last decade has seen an extraordinary amount of effort devoted in biomedical research to the field of biomarkers. There have been some notable successes with novel markers being adopted into clinical practice bringin...